Mylan (MYL) Plans to Launch Generic EpiPen; Will Cost 50% Less than Name Brand

BTIG Affirms Mylan (MYL) at 'Buy'; Generic EpiPen Highlights Challenges to U.S. Healthcare System

BTIG affirms Mylan (Nasdaq: MYL) with a Buy rating and $60 price target as the company moves to release a generic EpiPen.

Analyst Timothy Chiang commented today, While Mylan has dealt with much criticism from the media and politicians, we believe the measures the company has announced... More

Generic EpiPen to Hit Mylan (MYL) EPS by a Modest 2% - Leerink

Leerink Partners analyst Jason Gerberry weighed in on Mylan (NASDAQ: MYL) after the company announced the launch of a generic version of its EpiPen amid price scrutiny.

Gerberry estimates the launch of an EpiPen authorized generic (AG) will have a... More

Mylan's (MYL) Epipen4Schools Program is a Complicated Maze of Specialty Distribution Cos - Wells Fargo's Maris

Wells Fargo analyst David Maris explored Mylan's (NASDAQ: MYL) Epipen4Schools program. After reviewing the program he said it's "more complex than we thought". The way he described it it sounds eerily similar to what Valeant (NYSE: VRX) was doing with specialty pharmacy Philidor, although he didn't mention the Valeant comparison at all in his note.

First Maris notes that at the EpiPen4Schools.com webpage, Mylan's logo is displayed but also BioRidge Pharma.

They believe BioRidge Pharma is a specialty distribution company. Maris... More

Why All the Outcry About EpiPen Prices Now? It's Back to School Time

Evercore ISI's Mylan (NYSE: MYL) analyst, Umer Raffat, answered the question "why the pricing noise on Epipen started now all of a sudden?" His short answer "it's back to school time and this is when the highest volumes of Epipen are... More

PCMA: 'It Was Mistake for Mylan (MYL) to Adopt Pricing Strategy Used Unsuccessfully by Valeant (VRX), Turing'

The Pharmaceutical Care Management Association (PCMA) issued the following press release on Thursday:

Pharmaceutical Care Management Association (PCMA) President and CEO Mark Merritt issued the following statement on Mylan's EpiPen price hikes and attacks in the press on payers and pharmacy benefit managers (PBMs):

"It was a mistake for Mylan to adopt the failed PR strategy used unsuccessfully by Valeant... More

Elijah Cummings Says Mylan's (MYL) Meager Discount Merely 'PR Move'

Elijah Cummings Says Mylan's (Nasdaq: MYL) Meager Discount Merely 'PR Move'

Options with increasing volume: NYMX MYL ULTA

Options with increasing volume: NYMX MYL ULTA RIO SWN PAAS GES BIG AGEN SPA DF RDUS WSM DLTR GES TIF HPQ AXP

Wall St. slips on healthcare, consumer names; Fed eyed

By Chuck Mikolajczak

NEW YORK (Reuters) - U.S. stocks were modestly lower on Thursday, weighed down by a drop in healthcare and consumer names, while financials advanced slightly after two more Federal Reserve officials pushed the case for a rate hike.

Healthcare stocks , down 0.8 percent, came under pressure for a second straight day. St. Jude Medical (NYSE: STJ) shares fell 5 percent after short-selling firm Muddy Waters said it bet that the shares would fall because of cyber security vulnerabilities in the company's cardiac devices.

Mylan NV (NASDAQ:... More

Mylan (MYL) CEO says healthcare bubble 'going to burst'

Mylan (NASDAQ: MYL) CEO says healthcare bubble 'going to burst'.